Telix Pharmaceutical/$TLX
1D1W1MYTD1Y5YMAX
Capital at risk
About Telix Pharmaceutical
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
- Ticker
- $TLX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,152
- Headquarters
- North Melbourne, Australia
- Website
- telixpharma.com
TLX Metrics
BasicAdvanced
$4.3B
134.51
$0.10
0.60
-
Price and volume
Market cap
$4.3B
Beta
0.6
52-week high
$13.11
52-week low
$6.28
Average daily volume
221K
Financial strength
Current ratio
2.014
Quick ratio
1.743
Long term debt to equity
1.157
Total debt to equity
1.189
Interest coverage (TTM)
3.69%
Profitability
EBITDA (TTM)
69.806
Gross margin (TTM)
47.57%
Net profit margin (TTM)
3.76%
Operating margin (TTM)
6.20%
Effective tax rate (TTM)
-16.24%
Revenue per employee (TTM)
$770,000
Management effectiveness
Return on assets (TTM)
2.71%
Return on equity (TTM)
7.37%
Valuation
Price to earnings (TTM)
134.506
Price to revenue (TTM)
4.924
Price to book
12.37
Price to tangible book (TTM)
-62.22
Price to free cash flow (TTM)
-93.739
Free cash flow yield (TTM)
-1.07%
Free cash flow per share (TTM)
-0.137
Growth
Revenue change (TTM)
33.49%
Earnings per share change (TTM)
174.82%
3-year revenue growth (CAGR)
53.38%
3-year earnings per share growth (CAGR)
-2.87%
Bulls say / Bears say
Telix’s commercial engine is scaling: first-half revenue rose 22% to US$477 million, Precision Medicine revenue rose 27%, and its 65% segment gross margin helped management track towards the top of its US$950–970 million full-year guidance. (PR Newswire)
FDA approval of Pixclara adds a third approved imaging product and gives Telix an entry into the US glioma-imaging market, reducing its reliance on prostate-cancer imaging alone. (Kalkine)
The Regeneron collaboration gives Telix access to antibody-discovery expertise while providing a non-refundable US$40 million upfront payment, helping fund development of next-generation radiopharmaceuticals without immediate equity issuance. (GlobeNewswire, PR Newswire)
The headline profit is not fully repeatable: H1 profit after tax of US$38 million included the US$40 million Regeneron payment, while R&D rose to US$124 million and full-year R&D guidance is US$230–270 million. (PR Newswire)
The longer-term therapeutic opportunity remains unproven because TLX591-Tx, TLX101-Tx and TLX250-Tx are still investigational, while Zircaix was still undergoing work on a BLA resubmission in the latest update. (PR Newswire, GlobeNewswire)
The balance sheet now carries US$600 million of convertible bonds due in 2031, and H1 finance costs were US$19 million; conversion could dilute shareholders and the debt adds pressure if cash generation weakens. (PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
Upcoming events
No upcoming events
TLX News
AllArticlesVideos
Funds containing TLX
AllEURGBPUSD
Fund name | Fund size | $TLX weighting |
|---|---|---|
Vanguard FTSE Developed Asia Pacific ex Japan€VAPX | €1.8B | 0.05% |
Vanguard FTSE Developed Asia Pacific ex Japan£VAPX | £1.6B | 0.05% |
iShares MSCI World Small Cap$WSML | $9B | 0.03% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.03% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.